Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.33 EUR | +2.10% | +13.85% | +47.90% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
Sales 2023 | 2.23M 2.4M | Sales 2024 * | 37.83M 40.74M | Capitalization | 137M 147M |
---|---|---|---|---|---|
Net income 2023 | -23M -24.77M | Net income 2024 * | -5M -5.38M | EV / Sales 2023 | 36.2 x |
Net Debt 2023 * | 33.7M 36.3M | Net Debt 2024 * | 46.6M 50.18M | EV / Sales 2024 * | 4.84 x |
P/E ratio 2023 |
-3.63
x | P/E ratio 2024 * |
-14.7
x | Employees | 62 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 72.4% |
Latest transcript on OSE Immunotherapeutics
1 day | +2.10% | ||
1 week | +13.85% | ||
Current month | +12.23% | ||
1 month | +30.25% | ||
3 months | +71.54% | ||
6 months | +33.40% | ||
Current year | +47.90% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Nicolas Poirier
CEO | Chief Executive Officer | 42 | 16-05-30 |
Director of Finance/CFO | - | 16-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Director/Board Member | 66 | 23-06-21 | |
Director/Board Member | 66 | 22-02-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 6.33 | +2.10% | 166,796 |
24-05-03 | 6.2 | -0.64% | 222,290 |
24-05-02 | 6.24 | +10.64% | 579,101 |
24-04-30 | 5.64 | +2.17% | 95,863 |
Real-time Euronext Paris, May 06, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.90% | 144M | |
+22.81% | 47.9B | |
+46.56% | 41.42B | |
-1.88% | 40.7B | |
-6.20% | 28.92B | |
+11.33% | 25.55B | |
-21.00% | 19.27B | |
-1.43% | 12.15B | |
+30.73% | 12.14B | |
-0.48% | 11.99B |
- Stock Market
- Equities
- OSE Stock